Boston Partners’s Augmedix, Inc. Common Stock AUGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-314,067
| Closed | -$738K | – | 773 |
|
|
2024
Q3 | $738K | Buy |
314,067
+4,757
| +2% | +$9.6K | ﹤0.01% | 639 |
|
|
2024
Q2 | $272K | Buy |
309,310
+170,902
| +123% | +$352K | ﹤0.01% | 688 |
|
|
2024
Q1 | $566K | Buy |
138,408
+54,372
| +65% | +$243K | ﹤0.01% | 675 |
|
|
2023
Q4 | $492K | Buy |
84,036
+21,157
| +34% | +$111K | ﹤0.01% | 612 |
|
|
2023
Q3 | $324K | Sell |
62,879
-61,445
| -49% | -$288K | ﹤0.01% | 687 |
|
|
2023
Q2 | $598K | Sell |
124,324
-353,421
| -74% | -$1.22M | ﹤0.01% | 597 |
|
|
2023
Q1 | $831K | Buy |
477,745
+351,279
| +278% | +$573K | ﹤0.01% | 540 |
|
|
2022
Q4 | $197K | Buy |
126,466
+28,950
| +30% | +$36.9K | ﹤0.01% | 670 |
|
|
2022
Q3 | $141K | Buy |
97,516
+1,073
| +1% | +$1.84K | ﹤0.01% | 687 |
|
|
2022
Q2 | $174K | Sell |
96,443
-10,264
| -10% | -$23.8K | ﹤0.01% | 673 |
|
|
2022
Q1 | $314K | Buy |
106,707
+14,516
| +16% | +$39.4K | ﹤0.01% | 652 |
|
|
2021
Q4 | $290K | Buy |
+92,191
| New | +$334K | ﹤0.01% | 646 |
|
Boston Partners's AUGX Position: Q4 2024 in Review
Boston Partners sold out of Augmedix, Inc. Common Stock (AUGX) in Q4 2024, closing a stake of 314,067 shares — an estimated $738K sold.
Boston Partners first reported a position in AUGX in Q4 2021 and held it in 12 quarters. The position peaked at $831K in Q1 2023. 0 funds tracked by Wall St. Rank hold AUGX as of Q4 2024.
- Boston Partners reported no remaining Augmedix, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Boston Partners sold 314,067 Augmedix, Inc. Common Stock shares in Q4 2024, an estimated $738K.
- Boston Partners first reported a position in Augmedix, Inc. Common Stock in Q4 2021 and held it in 12 quarters.
- Boston Partners's Augmedix, Inc. Common Stock position peaked at $831K in Q1 2023.
- 0 funds tracked by Wall St. Rank held Augmedix, Inc. Common Stock as of Q4 2024.
Based on Boston Partners's 13F filing for Q4 2024, filed 11 Feb 2025.